Tellgen

Tellgen EBIT Growth

The Year-over-Year EBIT Growth of Tellgen (300642.SZ) as of Nov 2, 2026 is -0.32 %. In the previous year, Year-over-Year EBIT Growth was -56.29 % — a change of -99.44% (higher).

EBIT Growth

-0.32 %

YoY

-99.44%

Last updated:

Year-over-Year EBIT Growth of Tellgen is 2025 -0.32 % . Year-over-Year EBIT Growth of Tellgen was 2024 -56.29 % . It decreases by -99.44% higher compared to the previous year.

The Tellgen EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
12.37 CNY
Jan 1, 2019
9.91 CNY
Jan 1, 2020
-27.26 CNY
Jan 1, 2021
36.51 CNY
Jan 1, 2022
-27.20 CNY
Jan 1, 2023
-32.77 CNY
Jan 1, 2024
-56.29 CNY
Jan 1, 2025
-0.32 CNY
The Tellgen EBIT Growth history
YEAREBIT GrowthYoY
-0.32 %-99.44%
-56.29 %+71.76%
-32.77 %+20.48%
-27.20 %-174.49%
36.51 %-233.94%
-27.26 %-375.14%
9.91 %-19.93%
12.37 %-67.94%
38.60 %-17.21%
46.62 %-40.46%
78.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Tellgen Stock analysis

What does Tellgen do? Tellgen Corp develops, manufactures, and markets molecular diagnostic products including immunodiagnostic, molecular diagnostic, and biochemical diagnostic products. Their portfolio features tumor marker detection, HPV nucleic acid testing, autoimmune disease detection, and lung cancer methylation mutation detection products. The company targets healthcare providers and laboratories seeking advanced diagnostic solutions for disease detection and monitoring. Tellgen Corp generates revenue through the sale of these specialized diagnostic products to medical institutions and healthcare facilities. The firm's product lines focus on specific diagnostic needs such as cancer screening and infectious disease testing. Immunodiagnostic products detect antibodies and antigens, molecular diagnostic products analyze genetic material, and biochemical diagnostic products measure metabolic markers. Tellgen Corp sells these products directly to hospitals, clinics, and diagnostic laboratories across China and potentially internationally. Tellgen Corp's revenue streams come from the commercialization of its diagnostic product portfolio. The company's offerings address key healthcare challenges including early cancer detection and infectious disease management. Their products are designed to support clinical decision-making and patient care pathways in medical settings. Tellgen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tellgen stock

Year-over-Year EBIT Growth of Tellgen is -0.32 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Tellgen since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Tellgen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Tellgen

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Tellgen